Intrust Bank NA Increases Stock Holdings in Booz Allen Hamilton Holding Co. Wells Fargo & Company MN Grows Position in Vanguard Mid-Cap Growth ETF, Wells Fargo & Company MN Grows Position in Vanguard Health Care Index Fund ETF Shares. NASDAQ 0.00%. Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q4 2020 Results - Earnings Call Transcript, Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment as likely contributor to unusually high placebo effect in TRILOGY 1, Plans to report summary of Trilogy 1 data on June 29, 2020 conference call Plans to report summary of Trilogy 1 data on June 29, 2020 conference call, FDA response expected on or before June 30, 2020, Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids Expands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids. Oppenheimer cut shares of Acasti Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, August 31st. If they plan on doubling-down on CaPre, they need more capital. Cancel. Acasti Pharma (ACST) is having trouble on Monday as ACST stock has fallen a great deal, but what's behind the falling prices? Intrust Bank NA Purchases Shares of 6,863 Newmont Co. Air France-KLM SA Receives Average Recommendation of “Sell” from Analysts. A hedge fund recently bought a new stake in Acasti Pharma stock. For exchange delays and terms of use, please read disclaimer (will open in new tab). Acasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2019 Results - Earnings Call Transcript. Here's why you should pay attention to the stock now. © Copyright 2020 The Globe and Mail Inc. All rights reserved. Wells Fargo & Company MN Has $236.32 Million Stock Position in Burlington Stores, Inc. Acasti Pharma Inc. (NASDAQ:ACST) was the target of a large growth in short interest during the month of September. Finally, Echelon Wealth Partners restated a “buy” rating and set a $1.40 target price on shares of Acasti Pharma in a research note on Tuesday, June 30th. To view this site properly, enable cookies in your browser. Acasti Pharma stock plunged after disappointing TRILOGY 1 trial results. Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings. That makes Acasti Pharma stock a liability, not a bargain. Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of … Towards this end, the Company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist in the process. Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed. The stock has a market cap of $19.65 million, a price-to-earnings ratio of -0.63 and a beta of 1.89. View which stocks have been most impacted by … It doesn't look good for Acasti Pharma stock. Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2020 Results - Earnings Call Transcript. 2.93% of the stock is currently owned by hedge funds and other institutional investors. Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History. Available for free with registration. On average, equities research analysts predict that Acasti Pharma will post -0.2 earnings per share for the current year. Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share. MarketBeat.com's FREE daily email newsletter. Seeking Alpha - 3 months ago Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q4 2020 Results - Earnings Call Transcript For subscribers only. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings results on Thursday, August 13th. LAVAL, Québec, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has appointed seasoned financial executive Bri... LAVAL, Québec, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST) announced that it has filed and mailed the information circular ... CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint CaPre achieved a 30.4% median ... Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Sign Up. Several brokerages have recently weighed in on ACST. Virtu Financial LLC owned about 0.28% of Acasti Pharma as of its most recent SEC filing. What this means: InvestorsObserver gives Acasti Pharma (ACST) an overall rank of 34, which is below average. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.34 and a current ratio of 2.34. Real-time trade and investing ideas on Acasti Pharma Inc. ACST from the largest community of traders and investors. Shares of Amarin Corp. PLC AMRN, +4.80% rose 4.8% in active afternoon trading Monday, after makers of drugs that rival Amarin's Vascepa, which is used to lower the risk of cardiovascular event... Shares of Acasti Pharma Inc (NASDAQ: ACST), which closed at $2.18 Friday, have entered penny stock territory after a negative data readout. However, without FDA approval, the underlying pharmaceutical is merely a gamble. How does the Beige Book influence monetary policy? Acasti Pharma stock plunged after the company reported negative trial results. Virtu Financial LLC bought a new position in Acasti Pharma Inc. (NASDAQ:ACST) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 252,405 shares of the biopharmaceutical company’s stock, valued at approximately $118,000. Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter. Acasti Pharma lost $118 million in market capitalization on January 13. Pre-Market Earnings Guidance, Affimed (NASDAQ:AFMD) Short Interest Update, Air France-KLM SA (OTCMKTS:AFLYY) Receives Average Recommendation of “Sell” from Analysts, Intrust Bank NA Increases Stock Holdings in Booz Allen Hamilton Holding Co. (NYSE:BAH), Intrust Bank NA Purchases Shares of 6,863 Newmont Co. (NYSE:NEM), Wells Fargo & Company MN Grows Position in Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT), Wells Fargo & Company MN Has $220.21 Million Stock Holdings in DocuSign, Inc. (NASDAQ:DOCU), Wells Fargo & Company MN Has $236.32 Million Stock Position in Burlington Stores, Inc. (NYSE:BURL), Wells Fargo & Company MN Grows Position in Vanguard Health Care Index Fund ETF Shares (NYSEARCA:VHT), Wells Fargo & Company MN Boosts Stock Position in Bright Horizons Family Solutions Inc. (NYSE:BFAM), Wells Fargo & Company MN Increases Stock Holdings in Teledyne Technologies Incorporated (NYSE:TDY), Wells Fargo & Company MN Boosts Position in Manulife Financial Co. (NYSE:MFC), IHS Markit Ltd. (NYSE:INFO) Position Lowered by Wells Fargo & Company MN, Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Wells Fargo & Company MN, WNS (Holdings) Limited (NYSE:WNS) Receives $68.50 Consensus PT from Analysts, Benefitfocus, Inc. (NASDAQ:BNFT) Receives Consensus Recommendation of “Hold” from Brokerages, Wells Fargo & Company MN Acquires 200,251 Shares of Black Knight, Inc. (NYSE:BKI), Wells Fargo & Company MN Acquires 32,924 Shares of Monolithic Power Systems, Inc. (NASDAQ:MPWR), Contrasting Diginex (EQOS) and The Competition, Shopify Inc. (NYSE:SHOP) Position Lessened by Wells Fargo & Company MN, Analysts Set Cameco Co. (NYSE:CCJ) Price Target at $15.30. A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. One of the primary causes of con... Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1. The company's road ahead is filled with risks. Rooms Rankings Earnings Calendar Shop. Takes you to an interactive chart which cannot interact. DOW 0.00%. Acasti Pharma is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Mr. Ford assumes the responsibilities formerly held by Jean-Francois Boily, Vice-President, Finance, who recently resigned. Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021 feeds.benzinga.com - August 13 at 8:52 AM: Why Acasti Pharma's Stock Is Trading Higher Today finance.yahoo.com - July 6 at 10:38 PM: Why Acasti Pharma's Stock Is Trading Higher Today www.benzinga.com - July 6 at 5:38 PM: Acasti Pharma files for $200M mixed shelf The post Acasti Pharma News: Why ACST Stock Is Plummeting 24% Toda... On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020.